二仙壮骨汤与生骨胶囊口服结合人工股骨头置换术治疗老年股骨近端骨质疏松骨折的临床研究  

A clinical study on treating senile proximal femoral osteoporotic fracture with the Erxian Zhuanggu decoction plus the Shenggu capsules and artificial femoral head replacement

作　　者：郭永林 李巍 姜升平 曹谦 汤智 罗纯清 蒲云青 贺璐 廖速成 GUO Yonglin

机构地区：[1]湖南省湘潭市中医医院,湖南湘潭411100

出　　处：《中医临床研究》2024年第32期140-144,共5页Clinical Journal Of Chinese Medicine

基　　金：湘潭市医学科研项目(2020xtyx-46);湖南省中西医结合骨伤临床医疗技术示范基地项目(2023SK4064);湘潭市老年股骨近端骨折临床医疗技术示范基地项目(SF-LCYL20191002);湘潭市首轮医卫名家培育工程项目(潭卫发[2020]1号)。

摘　　要：目的:探究二仙壮骨汤与生骨胶囊口服结合人工股骨头置换术在老年股骨近端(髋部)骨质疏松骨折中的临床应用效果。方法:选择2020年3月-2023年2月在湖南省湘潭市中医医院就诊的老年骨质疏松性髋部骨折行人工股骨头置换手术的患者90例,按照随机数字表法分为试验组、对照组1、对照组2。试验组患者予院内自拟方二仙壮骨汤(经验方)及自制剂生骨胶囊口服,对照组1予阿仑膦酸钠片口服,对照组2不予特殊治疗,治疗时间为24周,对比三组患者用药前后中医证候积分、髋关节功能、骨密度等指标的差异。结果:试验组患者治疗后中医证候积分较治疗前显著降低,且试验组患者中医证候积分显著低于其他两组,差异有统计学意义(P<0.05);对照组1与对照组2患者中医证候积分的差异无统计学意义(P>0.05)。试验组、对照组1患者治疗后髋关节功能各项评分、骨密度、碱性磷酸酶(Alkaline Phosphatase,ALP)、I型前胶原氨基端前肽(Procollagen I N-Terminal Propeptide,PINP)、骨钙素(Bone Glaprotein,BGP)水平显著高于治疗前,且骨密度、ALP、PINP、BGP水平显著高于对照组2,差异有统计学意义(P<0.05),但试验组与对照组1的差异无统计学意义(P>0.05)。结论:二仙壮骨汤联合生骨胶囊口服可以有效改善骨质疏松型髋部骨折行人工股骨头置换术后患者的临床症状及髋关节功能,提高骨密度及骨转化指标水平。Objective:To explore the clinical application effect of the Erxian Zhuanggu decoction(二仙壮骨汤)plus the Shenggu Ocapsules(生骨胶囊)and artificial femoral head replacement on senile proximal femoral osteoporotic fractures in elderly patients.Methods:Ninety cases of senile proximal femoral osteoporotic fractures received artificial femoral head replacement surgery from March 2020 to February 2023 were selected and randomly divided into three groups according to the random number table method.Patients in the experimental group were given the self-prescribed formulas,the Erxian Zhuanggu decoction(empirical formula)and the Shenggu capsules orally,while the control group 1 was given oral administration of alendronate sodium tablets,the control group 2 received no special treatment.The treatment lasted for 24 weeks,and the differences in TCM syndrome scores,hip joint function,and bone mineral density before and after treatment were compared among the three groups.Results:The TCM syndrome scores of patients in the experimental group after treatment were significantly reduced compared with those before treatment,and the TCM syndrome scores of patients in the experimental group were significantly lower than those in the other two groups,with statistically significant differences(P<0.05).There was no difference in the TCM syndrome score between the control group 1 and the control group 2(P>0.05).After treatment,the hip joint function scores,bone mineral density,ALP,PINP,and BGP of patients in the experimental group and the control group 1 were significantly higher than those before treatment,and the bone mineral density,ALP,PINP,and BGP of patients in the experimental group and the control group 1 were significantly higher than those in the control group 2,with statistically significant differences(P<0.05).However,there was no difference between the experimental group and the control group 1(P>0.05).Conclusion:The Erxian Zhuanggu decoction plus the Shenggu capsule orally can effectively ameliorate the clinical sy

关 键 词：股骨近端骨折 骨质疏松 老年患者 二仙壮骨汤 

分 类 号：R274[医药卫生—中医骨伤科学]